<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04575363</url>
  </required_header>
  <id_info>
    <org_study_id>PA20113</org_study_id>
    <nct_id>NCT04575363</nct_id>
  </id_info>
  <brief_title>RPSA as a Potential Prognostic Biomarker of Pancreatic Cancer</brief_title>
  <acronym>PaCaBioMarkeR</acronym>
  <official_title>RPSA as a Potential Prognostic Biomarker of PDAC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Reims</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PDAC (Pancreatic ductal adenocarcinoma) represents 90% of pancreatic tumors. The prognosis of&#xD;
      PDAC remains poor at this time. Its management is based on surgery for early stages,&#xD;
      associated with neoadjuvant and adjuvant chemotherapy. However, around 80% of patients will&#xD;
      relapse after surgery. There is a lack of efficient biological biomarkers of PDAC, especially&#xD;
      for prognosis. To date, CA19-9 is commonly used despite its lack of sensitivity and&#xD;
      specificity.&#xD;
&#xD;
      Ribosomal protein SA (RPSA) is a transmembrane receptor localized at the cell surface but&#xD;
      also in the cytosolic and nuclear regions. RPSA interacts with many proteins in the&#xD;
      extracellular matrix (ECM), including laminin-1 and elastin. RPSA in involved in different&#xD;
      cellular functions such as cell adhesion, migration, proliferation and differentiation. The&#xD;
      expression of RPSA is increased in many cancers including breast, lung, prostate, pancreatic,&#xD;
      etc. It could represent a molecular biomarker of tumor invasion and metastatic abilities.&#xD;
      Moreover, the concentration of RPSA could be measured in the serum of patients with PDAC.&#xD;
      Recent data suggest that a modification of the RPSA concentration could be a prognostic&#xD;
      biomarker of PDAC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to explore the potential implication of RPSA as prognostic biomarker&#xD;
      of PDAC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RPSA serum concentration</measure>
    <time_frame>Day 0</time_frame>
    <description>The RPSA serum concentration is assessed with commercially available RPSA ELISA assay (MyBioSource - MBS9137288).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma (PDAC)</condition>
  <arm_group>
    <arm_group_label>pancreatic adenocarcinoma patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient with pancreatic ductal adenocarcinoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Blood sample</description>
    <arm_group_label>pancreatic adenocarcinoma patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        inclusion criteria :&#xD;
&#xD;
          -  Patients treated at the Reims University Hospital for a resectable or potentially&#xD;
             resectable pancreatic tumor, with or without neoadjuvant chemotherapy&#xD;
&#xD;
          -  Adults (aged more than 18 years old)&#xD;
&#xD;
          -  Patients who have signed the informed consent form&#xD;
&#xD;
        exclusion criteria :&#xD;
&#xD;
          -  Patients with a prior history of cancer (excluding basal cell carcinoma or in situ&#xD;
             cervical cancer that received conventional cancer treatment).&#xD;
&#xD;
          -  Minors&#xD;
&#xD;
          -  Patients for whom PDAC is not the retained diagnosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Baptiste OUDART</last_name>
    <phone>03 10 73 62 87</phone>
    <phone_ext>0033</phone_ext>
    <email>joudart@chu-reims.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Damien JOLLY</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-Baptiste OUDART</last_name>
      <phone>03 10 73 62 87</phone>
      <email>joudart@chu-reims.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic ductal adenocarcinoma</keyword>
  <keyword>Ribosomal protein SA (RPSA)</keyword>
  <keyword>prognosis biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

